November 18, 2010
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
Otsuka Pharmaceutical Co., Ltd. today announced that it has applied for regulatory approval in Japan for an additional indication of L-Cartin® tablets (nonproprietary name: levocarnitine chloride) for carnitine deficiency, based on the evidences in the public domain.
Information in this news release was current as of the original release date.